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Objective: The optimal strategy for treating hepatocellular carcinoma (HCC), a disease with increasing
incidence, in patients with Child–Pugh class A cirrhosis has long been debated. This study evaluated the
cost-effectiveness of hepatic resection (HR) or locoregional therapy (LRT) followed by salvage orthotopic
liver transplantation (SOLT) vs. that of primary orthotopic liver transplantation (POLT) for HCC within the
Milan Criteria.
Methods: A Markov-based decision analytic model simulated outcomes, expressed in costs and
quality-adjusted life years (QALYs), for the three treatment strategies. Baseline parameters were deter-
mined from a literature review. Sensitivity analyses tested model strength and parameter variability.
Results: Both HR and LRT followed by SOLT were associated with earlier recurrence, decreased
survival, increased costs and decreased quality of life (QoL), whereas POLT resulted in decreased
recurrence, increased survival, decreased costs and increased QoL. Specifically, HR/SOLT yielded
3.1 QALYs (at US$96 000/QALY) and LRT/SOLT yielded 3.9 QALYs (at US$74 000/QALY), whereas POLT
yielded 5.5 QALYs (at US$52 000/QALY). Sensitivity analyses supported these findings at clinically mean-
ingful probabilities.
Conclusions: Under the Model for End-stage Liver Disease (MELD) system, in patients with HCC within
the Milan Criteria, POLT increases survival and QoL at decreased costs compared with HR or LRT
followed by SOLT. Therefore, POLT is the most cost-effective strategy for the treatment of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the most common
primary liver cancer worldwide, with an estimated incidence of
500 000–750 000 cases annually.1 Although HCC is historically a
tumour of the Asian and African continents, its incidence has been
increasing in the Western world. The annual age-adjusted inci-
dence of HCC in the USA more than tripled between 1975 and
2005 from 1.6 to 4.9 per 100 000 population.2 Survival rates in the
USA have also increased over that period, probably as a result of
earlier detection and identification of smaller and more treatable
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tumours. Survival at 1 year in patients treated (via all modalities)
for localized HCC may reach 80–90%.2
However, even as survival rates have increased in the USA over
the past decade, the best strategy for treating HCC in patients with
Child–Pugh class A cirrhosis is still under debate. Despite high
recurrence rates, surgical resection has been the standard treat-
ment in cirrhotic patients without extrahepatic disease and with
sufficient liver function. Early experiences with liver transplanta-
tion (LT) as a curative therapy for HCC resulted in poor results
and high recurrence rates; however, tumour characteristics could
be used to select the most suitable candidates.3,4 In 1996, Mazza-
ferro and colleagues described their protocol for identifying which
patients with HCC were candidates for transplantation.5 This pro-
tocol became what is now commonly known as the Milan Criteria,
which indicate that a subject is a transplant candidate if he or she
has a single tumour measuring5 cm or three or fewer tumours,
each 3 cm. Prior to the implementation of the Model for End-
stage Liver Disease (MELD) allocation system, wait times were
prohibitively long and many patients with HCC died as a result of
tumour progression.6 Under the MELD system, candidates with
tumours within the Milan Criteria are preferentially transplanted
and the number of persons removed from the wait list as a result
of tumour progression has declined.7,8 More recently, the use
of locoregional therapies (LRTs), particularly radiofrequency
ablation (RFA), has increased as both primary therapy for HCC
as well as for local tumour treatment in anticipation of
transplantation.9–11
Surgeons now have several primary and salvage treatment
options available for patients with HCC and compensated cirrho-
sis. The aim of this study was to evaluate the cost-effectiveness of
hepatic resection (HR) or LRT with RFA followed by salvage
orthotopic liver transplantation (SOLT) vs. that of primary ortho-
topic liver transplantation (POLT) for HCC within the Milan
Criteria.
Materials and methods
Markov decision model
TreeAge Pro 2009 (TreeAge Software, Inc., Williamstown, MA,
USA) was used to construct a Markov-based decision analytic
model to simulate outcomes for patients undergoing one of three
treatment strategies: (i) HR followed by SOLT; (ii) LRT followed
by SOLT, and (iii) POLT. The Markov-based decision analytic
technique begins by assigning a group (or groups) of hypothetical
patients to one or more health states and simulates their outcomes
over prespecified time intervals or cycles. These hypothetical
patients can move into and out of various health states after each
cycle until all of the patients have reached an ‘absorbing state’
(most commonly death). The absorbing state is, by definition, a
state that, once entered, cannot be left. Modelled probabilities of
transitioning between health states or staying within the same
health state for a given cycle are populated on the basis of a
thorough literature review. The accrued time in each health state,
and the associated values and costs associated with that health
state, are accumulated as patients move through each cycle. A
value, most commonly in units of quality-adjusted life years
(QALYs), is assigned to the presence of each patient within a
health state. These values are accrued over the number of cycles
needed for model completion. A cost per QALY for each patient
can then be calculated, which allows for direct comparison of the
value of each treatment strategy.12,13 This cost-effectiveness
analysis was performed and reported according to the guidelines
set forth by the Panel on Cost-Effectiveness in Health and
Medicine.14,15
Health states
Figure 1 represents the health states considered in the Markov
decision model. Patients can undergo one of HR, RFA or POLT.
Between interventions, patients enter one of several health states.
The selected therapy can be followed by death (the absorbing
state), tumour-free survival, survival with recurrence, or need for
salvage transplantation (for locoregional or resection choices).
The time horizon was 10 years.
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Figure 1 The Markov decision analytic model. Patients with hepato-
cellular carcinoma (HCC) could undergo one of three therapies
including primary orthotopic liver transplantation (OLT), hepatic
resection or locoregional therapy with radiofrequency ablation (RFA)
followed by salvage OLT. A 10-year time horizon was used in this
model with Markov transition states including survival, death, sur-
vival with recurrence, and wait list or salvage transplantation (for
locoregional and hepatic resection strategies only)
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Model assumptions
The model has several assumptions.
1 Hepatocellular carcinomas considered for these therapies fall
within the Milan Criteria, which dictate that a single nodule
must measure5 cm or no more than three nodules measuring
3 cm must be present. The minimum size is considered to be
2 cm, which allows patients to be eligible for the priority excep-
tion points that permit listing as a candidate for LT with the
United Network of Organ Sharing (UNOS). Significantly dif-
ferent MELD scores can then result in significantly heteroge-
neous wait times. To include both of these populations (with
tumours measuring 2 cm and <2 cm, respectively) in the
model would have made it difficult to interpret the results. The
model does not consider more detailed tumour features such as
vascular invasion, tumour differentiation or anatomic location,
which may change the treatment approach. All tumours are
assumed to be amenable to all three therapies.
2 All patients are considered to have Child–Pugh class A cirrhosis.
3 Locoregional therapy is modeled for RFA only because several
randomized controlled trials (RTCs) have demonstrated
the superiority of this modality over other locoregional
methods.16–18 Additionally, all LRT is assumed to be delivered
percutaneously.
4 All surgical resections of HCC were carried out via a
laparotomy.
5 Tumour recurrences after POLT were considered to occur
outside the Milan Criteria or at extrahepatic locations. There-
fore, patients who had recurrence after POLT were not recon-
sidered for salvage transplantation within the model.
Probability data
Table 1 demonstrates the probabilities and rates used in the base-
line analysis, as well as the ranges used for all sensitivity analyses.
These values are based on a critical review of the available litera-
ture on HCC. MEDLINE/PubMed was systematically searched for
all articles dating from 1995 to February 2011 that compared HR,
LRT and POLT, especially reviews and meta-analyses. Specific
search terms included: ‘hepatocellular carcinoma’, ‘hepatic resec-
tion’, ‘locoregional therapy’, ‘radiofrequency ablation’ and ‘liver
transplantation’. Given the enormity of the literature in these
areas, representative studies were selected and data from RCTs and
prospective studies were emphasized. Special care was taken to
ensure the range of all variables was extracted from the literature.
Through this literature survey, a baseline value and range for all
variables of interest were obtained.
Cost data
Table 1 presents all cost estimates and ranges. Cost data were
abstracted from published studies of institutional costs and
studies in which the Medicare database or similar was used for
cost analysis. All costs were approached from a societal basis
according to established recommendations.19 This vantage point
allows for comparisons with other studies with similar perspec-
tives and the interpretation of results in the public interest (as
opposed to that of a particular patient group), and incorporates
both positive and negative cost changes to the system as the result
of an intervention. To adjust for inflation, all monetary values
were adjusted to 2008 US dollars using the Consumer Price Index
for medical care (US Bureau of Labor Statistics; http://
www.bls.gov). Future costs and health benefits were discounted to
account for the cost of spending money now vs. in the future.20
The discount rate was held constant at 3%.
Utilities
The effectiveness of interventions was measured in terms of
QALYs. This measure of health value incorporates both quality of
life (QoL) and time into a composite statistic that allows for
comparison between health interventions. Quality of life is deter-
mined by the measurement of health utilities, which usually range
from 0 (utility of death) to 1 (utility of perfect health). Utilities
represent the actual or tested health preferences of groups of
patients, either presently ill or possibly ill in the future21 (Table 1).
Sensitivity analysis
Given the inherent uncertainty of any absolute value within the
model, one- and two-way sensitivity analyses were performed to
test the model conclusions based on variations in individual
model parameters. The ranges utilized for these analyses are
described in Table 1.
To integrate additional levels of uncertainty, multi-way proba-
bilistic sensitivity analyses using Monte Carlo methods, which
change all probabilities and costs within the model simulta-
neously,22 provided additional tests of model sensitivity to changes
in model parameters.
Results
Base case analysis
Given the relative frequency of hepatitis C virus (HCV) cirrhosis
as an indication for LT in patients with HCC, the base case patient
in this model was a 56-year-old man with HCV and HCC. The
results of the reference case analysis in the Markov model are
depicted in Table 2 and Fig. 2. Using a 10-year time horizon, HR
with SOLT resulted in costs of US$296 000 to achieve 3.1 QALYs,
or approximately US$96 000/QALY. Locoregional therapy with
SOLT resulted in costs of US$290 000 to achieve 3.9 QALYs, or
approximately US$74 000/QALY. Primary orthotopic LT resulted
in costs of US$286 000 to achieve 5.5 QALYs, or approximately
US$52 000/QALY. Therefore, the POLT treatment strategy was
superior to and dominated both HR followed by SOLT and LRT
followed by SOLT.
Sensitivity analyses
Because the baseline probabilities and costs used in this model
vary across centres and regions performing these procedures, one-
and two-way sensitivity analyses to test the validity of the conclu-
sions over a range of probabilities and costs were performed.
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Figure 3 demonstrates the results of a one-way sensitivity analysis
in which the probability of transplantation from the POLT wait
list is varied. The yearly rate of POLT for HCC on the wait list was
varied between 20% and 90%. The threshold value at which POLT
is no longer the dominant (superior) strategy is 48%. Therefore,
52% of patients per year on the POLT wait list with HCC would be
required to expire or experience tumour progression beyond the
Milan Criteria for LRT with SOLT to become the preferable strat-
Table 1 Transition probability estimates from the literature with ranges used for sensitivity analyses
Transition probabilities Baseline value Range References
Radiofrequency ablation
Post-procedure mortality 1% 1–3%
Decompensation 5% 3–10% 30,33–41
5-year survival 35% 15–50%
Annual HCC recurrence 50% 25–70%
Hepatic resection
Postoperative mortality 3% 1–7%
Decompensation 5% 3–10% 42–49
5-year survival 55% 40–70%
Annual HCC recurrence 20% 15–35%
Primary liver transplant
Waitlist dropout/death 20% 10–40% 24,42–48
Postoperative mortality 5% 3–8%
5-year survival 70% 60–80%
Salvage liver transplant
Waitlist dropout/death 10% 10–40% 24,39,42–48
Postoperative mortality 8% 3–10%
5-year survival 70% 60–80%
Cost, US$
Compensated cirrhosis/year 5 000 3 000–10 000
RFA 5 000 2 500–10 000
Hepatic resection 35 000 25 000–60 000 30,35,50,51
Post-RFA/resection care/year 3 500 1 000–5 000
Liver transplant 150 000 100 000–200 000
Post-OLT care/year 12 000 10 000–25 000
Utilities, QALY
Compensated cirrhosis 0.7 0.5–0.8
Post-RFA 0.7 0.5–0.8
Post-RFA recurrence 0.5 0.4–0.8 30,40,50–53
Post-resection 0.7 0.5–0.8
Post-resection recurrence 0.5 0.4–0.8
Post-liver transplant 0.8 0.6–0.9
HCC, hepatocellular carcinoma; RFA, radiofrequency ablation; OLT, orthotopic liver transplantation; QALY, quality-adjusted life year
Table 2 Results of the base case Markov decision analysis model
Strategy Cost, US$ Incremental
cost, US$
Effectiveness,
QALY
Incremental
effectiveness, QALY
Cost-effectiveness,
US$/QALY
POLT 286 000 – 5.5 – 51.8
RFA 290 000 4 000 3.9 -1.6 74.0
Resection 296 000 9 000 3.1 -2.5 96.1
Both RFA and hepatic resection are dominated by POLT
QALY, quality-adjusted life year; POLT, primary orthotopic liver transplantation; RFA, radiofrequency ablation
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egy. Figure 4 demonstrates the results of a one-way sensitivity
analysis in which annual survival after POLT is varied. The thresh-
old value at which POLT is no longer the dominant strategy is
83%. Therefore, if the mortality rate after POLT exceeds 17% per
year, LRT with SOLT becomes the preferable strategy. Figure 5
demonstrates the results of a two-way sensitivity analysis in which
the probability of POLT per year on the wait list is simultaneously
varied with the probability of tumour-free survival after LRT.
Other model parameters remained constant as performed in the
base case analysis. Over the range of clinically meaningful values
on both the x- and y-axes, only POLT and RFA present cost-
effective strategies within this model. As rates of transplantation
from the POLT wait list increase, the POLT strategy is clearly the
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Figure 2 Results of the base case analysis in the Markov model
comparing the cost-effectiveness of hepatic resection or locore-
gional therapy with radiofrequency ablation (RFA) followed by
salvage orthotopic liver transplantation (OLT) vs. primary OLT in
patients with Child–Pugh class A cirrhosis and hepatocellular carci-
noma within the Milan Criteria. Primary OLT is the most cost-
effective strategy at US$52 000 per quality-adjusted life year (QALY)
(US$286 000 achieves 5.5 QALYs)
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Figure 3 One-way sensitivity analysis varying the annual probability
of transplantation from the wait list for primary orthotopic liver trans-
plantation (OLT). The threshold value in which primary OLT is no
longer the dominant (most cost-effective) strategy is 48%. At annual
probabilities of transplantation from the wait list for primary OLT of
<48%, radiofrequency ablation (RFA) becomes the most cost-
effective intervention. QALY, quality-adjusted life year
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Figure 4 One-way sensitivity analysis varying annual survival after
primary orthotopic liver transplantation (OLT). The threshold value at
which primary OLT is no longer the dominant (most cost-effective)
strategy is 83%. If annual survival after OLT falls to <83%, radiofre-
quency ablation (RFA) becomes the most cost-effective strategy.
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Figure 5 Two-way sensitivity analysis simultaneously varying annual
probability of transplantation from the wait list for primary orthotopic
liver transplantation (OLT) and probability of tumour-free survival
after radiofrequency ablation (RFA). Primary OLT is clearly the domi-
nant strategy at rates of transplantation from the wait list per year of
>30% and rates of tumour-free survival after RFA of <75%. Hepatic
resection is not cost-effective within these clinically meaningful
ranges
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most cost-effective. Only at low probability of transplantation
from the wait list for POLT does the RFA strategy become domi-
nant. Primary LT is clearly the dominant strategy at rates within
expected values of POLT from the wait list per year (>30%) and
rates of tumour-free survival after LRT (<75%). Figure 6 demon-
strates the results of a two-way sensitivity analysis in which the
yearly probabilities of survival after POLT, and SOLT after HR and
LRT, were simultaneously varied. Other model probabilities
remained constant as performed in the base case analysis. Again,
over the range of clinically meaningful values on both the x- and
y-axes, only POLT and RFA present cost-effective strategies within
this model. As the annual probability of survival after POLT
decreases, RFA becomes the dominant strategy. Put another way,
POLT is the dominant strategy unless rates of yearly death after
POLT exceed 17%.
One-way and two-way sensitivity analyses were performed for a
variety of ranges for costs and utilities; POLT emerged as the
dominant strategy at all clinically relevant values. The only con-
texts in which SOLT become the dominant strategy were those in
which the cost of POLT exceeded US$350 000 or if the QALYs
achieved by POLT dropped to 0.5. Additionally, multi-way proba-
bilistic sensitivity analyses using Monte Carlo methods proved
POLT to be the dominant strategy at all clinically relevant values.
Discussion
This study uses a Markov decision analysis model to compare HR
or LRT with RFA followed by SOLT with POLT for the treatment
of HCC within the Milan Criteria in patients with Child–Pugh
class A cirrhosis. Although several studies have compared LT and
HR, this is one of the first to simultaneously examine these three
treatment strategies in this patient population using a Markov
decision analysis model and delineating the effectiveness of each
in terms of cost per QALY. In this model, POLT was clearly the
most cost-effective strategy, with gains of 5.5 QALYs at a cost of
US$52 000/QALY, which is clearly within range of the US$50 000/
QALY level that is deemed to represent a cost-effective interven-
tion.23 Additionally, one-, two- and multi-way sensitivity analyses
further demonstrated the dominance of this strategy in patients
with small HCC and compensated cirrhosis.
Most importantly, the model was robust to a wide range of
probabilities in the rate of wait list attrition caused by tumour
progression or death. In the USA, the percentage of patients trans-
planted for HCC ranges from 5% to 20% and the mean wait time
for LT for HCC within the Milan Criteria is 90 days.24 One of the
primary arguments against POLT for HCC concerns the scarcity
of organs and the assumption that offering resection or LRT fol-
lowed by salvage transplant allows donor organs to be more effec-
tively managed and reduces the likelihood of death on the wait
list. In order to account for this assumption, the wait list dropout
rate in the POLT strategy was doubled in the model in comparison
with that in the SOLT strategy (20% vs. 10%). Despite biasing the
model in favour of salvage transplantation in this manner, POLT
still provided better overall QoL at reduced costs over the patient’s
lifetime. Additionally, by increasing the rate of wait list dropout in
the POLT strategy, the model was able to account for increases in
the percentage of HCC patients represented on the wait list and
increases in wait times.
Several studies have examined the impact of LT vs. HR in this
patient population using Markov modelling. Sarasin and col-
leagues used a Markov model to evaluate immediate resection or
transplantation in patients with compensated cirrhosis and HCC
within the Milan Criteria.25 They demonstrated a survival benefit
of 1.0–4.7 years depending on the wait time, with a marginal
cost-effectiveness ratio of US$44 454 : 183 840 per additional life
year. Locoregional therapies were not considered in their analy-
sis.25 El-Serag and colleagues used a Markov decision analysis
model to evaluate 3-year survival in patients with small hepatic
nodules (<3 cm) who underwent diagnosis via computed tomog-
raphy (CT) imaging or image-guided biopsy followed by treat-
ment with LT, HR or trans-hepatic chemoembolization.26 In
patients diagnosed with HCC by alpha-feto protein (AFP) eleva-
tion and imaging, these authors demonstrated LT to have a 3-year
survival benefit over HR. As with previous studies, they noted the
shortage of organ supply and wait times as disadvantages to this
strategy.26 The present study’s results build on these findings26 by
including RFA as the LRT and by describing the QALYs for each
strategy. By expressing cost as cost per QALY, the cost-effectiveness
of these interventions can be utilized by physicians and policy-
makers to compare the effectiveness of these interventions with
that of others reported in the literature.
Although the optimal treatment strategy for HCC in patients
with Child–Pugh class A cirrhosis remains under debate, the
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Figure 6 Two-way sensitivity analysis simultaneously varying annual
probability of survival after primary orthotopic liver transplantation
(OLT) and after salvage OLT. Primary OLT is the dominant treatment
strategy at rates of survival >83%. Below this rate, salvage OLT after
radiofrequency ablation (RFA) becomes the dominant (most cost-
effective) strategy. Hepatic resection is not cost-effective within
these clinically meaningful ranges
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primary treatment challenge is to diagnose patients before the
disease progresses beyond the criteria for surgical or transplanta-
tion consideration or to extrahepatic dissemination. Several
studies have noted resectability at the time of diagnosis at ranges
of 10–20%.9 Sarasin and colleagues found that a targeted biannual
surveillance programme in cirrhotic patients with preserved liver
function increased life expectancy from 3 months to up to 9
months, depending on the patient’s age, the rate of cancer devel-
opment and the patient’s survival rates after surgical interven-
tion.27 They did not recommend screening for all cirrhotic
patients, but noted that increases in life expectancy that resulted
from the surveillance of patients with compensated cirrhosis were
similar to those found in other large-scale cancer screening pro-
grammes. In a 2007 analysis, Thompson Coon and colleagues
estimated that a biannual surveillance programme using AFP and
ultrasound could result in a 10-fold increase in the diagnosis of
small (<2 cm) HCC tumours.28 This increased rate of detection
would result in HCC tumours being amenable to surgical resec-
tion at more than three times the present rate. Unfortunately,
surveillance is not uniformly implemented. In a recent analysis
conducted by the National Cancer Institute’s Surveillance, Epide-
miology and End Results (SEER) registry and Medicare, Davila
and colleagues noted that surveillance in cirrhotic patients aged
>65 years occurs in <20% of patients.29 As optimal treatment
strategies are developed, cost-effective and easily applied surveil-
lance methods should be employed to increase the number of
patients eligible for curative therapy at the time of diagnosis.
Additionally, increased diagnosis of tumours within the Milan
Criteria will require additional grafts, probably by increasing rates
of both living donation and extended criteria donation.
Within the present model, it is assumed that patients were
amenable to all three treatment options at the time of presenta-
tion. However, many patients presenting with HCC within the
Milan Criteria, in addition to being ineligible for resection, are
ineligible for LRT, specifically RFA, because of the anatomic loca-
tion of the tumour(s). Tumours located high in the dome of the
liver, superficially at Glisson’s capsule or near to blood vessels or
biliary radicals are not amenable to this treatment modality. Lap-
aroscopic, laparoscopic hand-assisted and open RFA may circum-
vent some of these anatomic considerations, but these techniques
were not considered within this model. Increasing the invasiveness
of the LRT will not only affect direct and indirect cost estimates
attributable to the procedure, but will also impact on patients’
perceptions of the procedure, thereby possibly resulting in
decreased QoL and an overall increase in cost per QALY.
Bridging strategies with combinations of resection and LRT
will need to be tailored. Additionally, the use of chemotherapeu-
tics such as sorafenib (Nexavar®; Bayer HealthCare Pharmaceuti-
cals, Inc., Montville, NJ, USA) may further impact the equation.30
Actual treatment therapy and selection for LT may need to be
approached in tiers in which bridging therapy is considered first
and in which patients with HCC that is amenable to locoregional
or systemic therapies may need to be fully treated with those
therapies in order to provide maximal wait time prior to trans-
plantation. Once this therapy is complete or, more notably, if
tumours are minimally responsive to bridging therapy, patients
would then be considered for surgical intervention. Surgical inter-
vention would potentially include resection, but more ideally
transplantation, depending on the underlying liver function, ana-
tomic considerations of the HCC and the availability of donor
organs. Increased understanding of tumour biology and gross
morphology may indicate those patients who would benefit from
one treatment modality over another given their responsiveness to
chemotherapy, local treatment therapies and transplantation.31,32
The model demonstrates the dramatic benefit of primary LT for
HCC within the Milan Criteria (and >2 cm in size) under the
UNOS allocation scheme. When HCC lesions measure <2 cm,
other strategies may predominate, given significant differences in
MELD scores and therefore wait times for transplantation.
Naugler and Sonnenberg recently demonstrated the benefit of
immediate LRT (particularly RFA) over monitoring with intent to
transplant in the treatment of patients with cirrhosis and HCC
lesions of <2 cm.30 They found both a survival benefit and cost
savings with immediate treatment with RFA within their model.
As surveillance becomes more commonplace, the appropriate
strategies for the treatment of very small HCC will be refined.
The necessity of applying assumptions to any decision analytic
model creates the possibility that the model does not accurately
reflect the nuances and realities of every clinical situation. The
model was created on the assumption that each patient would be
equally amenable to each of the treatment strategies examined in
the model. Clearly, as noted above, not all patients present with
surgically curable disease by either partial HR or transplantation.
The model assumed that the post-transplantation costs and utili-
ties of patients undergoing transplantation were identical.
However, it is clear that complications arising from transplantation
may both increase costs and decrease patient-reported QoL values
after transplantation, and thus may change model outcomes.Addi-
tionally, tumours present in locations in which percutaneous inter-
ventions are not appropriate, but in which other mechanisms of
applying LRT, by laparoscopic or open techniques, may permit the
patient to realize the benefit of oncologic LRT. The model does not
account for alternative LRTs utilized by many transplant centres,
particularly trans-arterial chemoembolization. Decision analytic
models rely heavily on current and historic cost and utility data and
are most useful in identifying points of decision in any treatment
process. These decisions are associated with discrete costs. The
evolution of payment strategies, such as bundled payments, may
change the model costs and final model interpretation. Finally, all
decision analytic models are only as good as the literature that
informs the base case and sensitivity analyses.
Cirrhosis resulting in HCC is a global disease that is becoming
more prevalent. Treatment strategies must not only be clinically
effective, but must also be cost-effective within the system of
medical practice in which cirrhosis and HCC are encountered.
The present analysis demonstrates the benefit of LT for HCC
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patients with Child–Pugh class A cirrhosis within the Milan Cri-
teria. However, as surveillance is applied more consistently, the
number of tumours amenable to transplantation will increase,
which may further burden the limited supply of deceased donor
livers and will certainly require further exploration of extended
donation protocols and the expansion of living donation.28 As
transplantation continues to emerge as the superior strategy in
cost-effectiveness models such as that in the present study, we
need to be alert to the possibility of adverse consequences in other
transplant candidate populations. This will require ongoing eco-
nomic and utility analyses to optimize diagnostic and treatment
strategies within systems of care with finite health care resources.
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